Aurion Biotech begins dosing patients in phase 3 trial for corneal therapy
Tweet Send to a Friend
Aurion Biotech has started dosing the first patients in its ASTRA Phase 3 study evaluating AURN001, an investigational cell therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
